MYELOVAX™ is an investigational allogeneic cancer vaccine platform based on the local production of granulocyte-macrophage colony stimulating factor (GM-CSF) at the vaccine site to generate a systemic tumor-specific immune response.

The goal of cancer vaccines is to enable the immune system to mount an effective and durable response against the cancer cells when a low tumor burden exists. To date, cancer vaccines have mostly been used in various settings to prevent disease relapse.

MYELOVAX™ is being investigated in multiple myeloma in the post-CAR T setting.